3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Melanoma
5
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Interventions
Gemcitabine
43
pembrolizumab
36
Paclitaxel
36
Nivolumab
31
Docetaxel
29
Capecitabine
29
Bevacizumab
29
Oxaliplatin
28
Fluorouracil
28
Cisplatin
26
Leucovorin
24
Cyclophosphamide
23
Radiosurgery
20
Irinotecan
20
Carboplatin
20
aldesleukin
19
Cetuximab
19
Interleukin-2
16
fludarabine phosphate
15
fludarabine
15
Pemetrexed
15
Trastuzumab
14
Magnetic Resonance Spectroscopy
14
Ipilimumab
14
Fulvestrant
14
130-nm albumin-bound paclitaxel
14
Prednisone
13
Everolimus
13
Radiotherapy
12
Panitumumab
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
Neoplasm Metastasis
×
bempegaldesleukin
×
Clear all
NCT03785925
2023-03-28
PIVOT-10
Nektar Therapeutics
Phase 2
Completed
192 enrolled
16 charts
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts